The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults
Top Cited Papers
Open Access
- 31 May 2020
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 26 (7), 806-814
- https://doi.org/10.1177/1352458519845112
Abstract
Objectives: The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients. Methods: All serum samples for routine diagnostics from February 2014 to December 2017 were sent to the single central reference laboratory for the full-length MOG-IgG cell-based assay (CBA) in the Netherlands. Clinical data from patients known in our National ADS centre were available. Results: A total of 1414 samples of 1277 patients were received; of these, 92 patients (7%) were MOG-IgG-seropositive. The mean incidence was 0.16/100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In MOG-IgG-positive patients at the National ADS centre (61/92, 66%), the most common presenting phenotype is acute disseminated encephalomyelitis (ADEM, 56%) in children and optic neuritis (ON, 44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during median follow-up of 27.5 months. Patients were tested MOG-IgG-positive >200 months after the initial attack, suggesting an extended time to first relapse (TTFR). Longitudinal analysis of MOG-IgG (25/61, 41%) showed that 67% of the monophasic patients remain seropositive and 60% in relapsing patients. Majority of seronegative patients had no relapses (89%). Conclusion: This nationwide study shows that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people. The distribution over the clinical phenotypes differs between adults and children. Seropositivity can be maintained over years even without clinical activity, while seronegative patients generally had no relapses.Keywords
Funding Information
- Stichting MS Research
This publication has 32 references indexed in Scilit:
- Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in childrenNeurology Neuroimmunology & Neuroinflammation, 2015
- Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohortMultiple Sclerosis Journal, 2015
- Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the diseaseMultiple Sclerosis Journal, 2014
- Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative StudyJAMA Neurology, 2014
- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersNeurology, 2014
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitionsMultiple Sclerosis Journal, 2013
- Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson diseaseNeurology, 2013
- Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patientsMultiple Sclerosis Journal, 2011
- New concepts in the immunopathogenesis of multiple sclerosisNature Reviews Neuroscience, 2002
- A novel myelin-associated glycoprotein defined by a mouse monoclonal antibodyJournal of Neuroimmunology, 1984